Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 25Carcinoma, Non-Small-Cell Lung 6Melanoma 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1

Interventions

selpercatinib 2pembrolizumab 2Cisplatin 2repotrectinib 1pralsetinib 1entrectinib 1Fluorouracil 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Head and Neck Neoplasms × pembrolizumab × Clear all
NCT03765918 2026-05-12

MK-3475-689

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
714 enrolled 90 charts 1 FDA
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT02358031 2025-07-18

MK-3475-048

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 50 charts 1 FDA
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡